|
|
 | | | |
- close
- close
- close
- close
Somaxon Pharmaceuticals (SOMX) |
Benzinga
Mar 6
Comment
Pernix Therapeutics Holdings (NASDAQ: PTX) today announced the completion of its acquisition of Somaxon Pharmaceuticals, Inc. (“Somaxon”) (NASDAQ: SOMX) following the approval of the transaction by stockholders of Somaxon at the special...
Benzinga
Dec 17
Comment
Somaxon Pharmaceuticals, Inc.
(Nasdaq: SOMX) today announced that its licensee Paladin Labs Inc.
has received approval from Health Canada of Paladin's New Drug Submission
(NDS) for Silenor^® (doxepin) for the treatment and symptomatic relief...
Benzinga
Dec 11
Comment
Somaxon Pharmaceuticals (NASDAQ: SOMX) surged 93.20% to $2.84 at 9:45 am. Somaxon Pharma agreed to be acquired by Pernix Therapeutics Holdings (AMEX: PTX).
TNS (NYSE: TNS) climbed 43.54% to $20.90. TNS agreed to be bought by an affiliate of...
StreetInsider.com
Dec 11
Comment
Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) 105% HIGHER; Pernix Therapeutics Holdings, Inc. (AMEX: PTX) will acquire Somaxon in a stock-for-stock transaction with a total equity value of $25 million
TripAdvisor Inc. (NASDAQ: TRIP) INDICATED...
Benzinga
Dec 11
Comment
Pernix Therapeutics (NYSE: PTX) and
Somaxon Pharmaceuticals, Inc. (“Somaxon”) (NASDAQ: SOMX) today announced
that they have entered into a definitive merger agreement for Pernix to
acquire Somaxon in a stock-for-stock...
StreetInsider.com
Oct 31
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Somaxon+Pharmaceuticals%2C+Inc.+%28SOMX%29+Misses+Q3+EPS+by+30c/7832040.html for the full story.
StreetInsider.com
Oct 11
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Stock+Splits/Somaxon+%28SOMX%29+Announces+One-for-Eight+Stock+Split/7786461.html for the full story.
StreetInsider.com
Jul 24
Comment
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Somaxon+%28SOMX%29+Closes+9.4M+Direct+Offering%3B+Sees+Gross+Proceeds+of+%243M/7600914.html for the full story.
Globe Newswire
Jul 24
Comment
SAN DIEGO, July 24, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has completed its previously announced registered direct offering of approximately 9.4 million
Globe Newswire
Jul 20
Comment
SAN DIEGO, July 20, 2012 (GLOBE NEWSWIRE) -- Somaxon Pharmaceuticals, Inc. (Nasdaq:SOMX), a specialty pharmaceutical company, today announced that it has entered into definitive agreements to sell approximately 9.4 million shares of its common stock
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSISSomaxon Pharmaceuticals (NASDAQ SOMX) is a Specialty Pharmaceutical company focused on the in-licensing, development and commercialization of proprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area [1]
Company Overview
- Somaxon Pharamaceuticals was founded in 2003 in Solana Beach, CA.
- Its Initial Public Offering occured in December of 2005. The Fiscal Year ends on December 31st
Products
- Silenor
- Silenor is a drug that treats Insomnia. It was approved by the Food and Drug Administration (FDA) in March 2010.
References
| |||||||
